Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Breast-cancer"

165 News Found

MHRA clears inavolisib, offering new option for returning breast cancer
News | November 30, 2025

MHRA clears inavolisib, offering new option for returning breast cancer

The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy


Eli Lilly to unveil major breast cancer data at SABCS 2025
Clinical Trials | November 25, 2025

Eli Lilly to unveil major breast cancer data at SABCS 2025

Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival


Roche’s Giredestrant sets new benchmark in early breast cancer treatment
Clinical Trials | November 19, 2025

Roche’s Giredestrant sets new benchmark in early breast cancer treatment

The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival


Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial
Clinical Trials | November 10, 2025

Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial

While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage


Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer
Clinical Trials | October 17, 2025

Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer

Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents


Datroway delivers first-ever overall survival breakthrough in 1st-line metastatic triple-negative breast cancer without immunotherapy
Clinical Trials | October 07, 2025

Datroway delivers first-ever overall survival breakthrough in 1st-line metastatic triple-negative breast cancer without immunotherapy

Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population


FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Drug Approval | September 29, 2025

FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor


Enhertu improved in invasive disease-free survival in early breast cancer in DB-05
Clinical Trials | September 29, 2025

Enhertu improved in invasive disease-free survival in early breast cancer in DB-05

Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting


Zydus, Pinkathon to drive awareness on breast cancer across India
Healthcare | September 24, 2025

Zydus, Pinkathon to drive awareness on breast cancer across India

Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health